[HTML][HTML] Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors
Introduction Previous exploratory analysis of epidermal growth factor receptor (EGFR)
mutational status in tumor samples from randomized clinical studies suggested that patients …
mutational status in tumor samples from randomized clinical studies suggested that patients …
[HTML][HTML] EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non–small cell lung cancer
H Kimura, K Kasahara, K Shibata, T Sone… - Journal of Thoracic …, 2006 - Elsevier
Background The authors evaluate the efficacy and safety of gefitinib monotherapy in
chemotherapy-naive patients with advanced non–small-cell lung cancer (NSCLC). A …
chemotherapy-naive patients with advanced non–small-cell lung cancer (NSCLC). A …
High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma
VM Moiseyenko, SA Procenko, EV Levchenko… - Oncology Research …, 2010 - karger.com
Abstract Background: Several Asian studies demonstrated feasibility of front-line
administration of gefitinib for the treatment of non-small cell lung carcinomas (NSCLCs) …
administration of gefitinib for the treatment of non-small cell lung carcinomas (NSCLCs) …
Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑and third‑generation EGFR‑TKIs
AK Vaid, A Gupta, G Momi - … journal of oncology, 2021 - spandidos-publications.com
Abstract A substantial (40‑60%) proportion of patients with non‑small cell lung carcinoma
(NSCLC) have epidermal growth factor receptor (EGFR) mutations, a crucial therapeutic …
(NSCLC) have epidermal growth factor receptor (EGFR) mutations, a crucial therapeutic …
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
LV Sequist, RG Martins, D Spigel… - Journal of clinical …, 2008 - ascopubs.org
Purpose Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
PURPOSE: Epidermal growth factor receptor (EGFR) mutations have been found in the
majority of gefitinib-responsive non-small cell lung cancer (NSCLC) patients from …
majority of gefitinib-responsive non-small cell lung cancer (NSCLC) patients from …
[HTML][HTML] Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus …
Abstract Objective The Phase III, randomized, open-label IPASS study (NCT00322452) of
first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) gefitinib …
first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) gefitinib …
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations
K Asami, T Okuma, T Hirashima, M Kawahara, S Atagi… - Lung Cancer, 2013 - Elsevier
BACKGROUND: Gefitinib is an effective treatment for patients with non-small cell lung
cancer who harbor activating epidermal growth factor receptor (EGFR) mutations. However …
cancer who harbor activating epidermal growth factor receptor (EGFR) mutations. However …
Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients
K Chen, X Yu, H Wang, Z Huang, Y Xu, L Gong… - Cancer Chemotherapy …, 2017 - Springer
Purpose Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …
Combination of chemotherapy and gefitinib as first‐line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized …
B Han, B Jin, T Chu, Y Niu, Y Dong, J Xu… - … journal of cancer, 2017 - Wiley Online Library
To explore the optimal treatment strategy for patients who harbor sensitive EGFR mutations,
a head‐to‐head study was performed to compare chemotherapy and gefitinib in …
a head‐to‐head study was performed to compare chemotherapy and gefitinib in …